Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?

References

• Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, . Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304–1313.
   PubMed Web of Science ®Google Scholar
• Witko V, Nguyen AT, Descamps-Latscha B. Microtiter plate assay for phagocyte-derived taurine-chloramines. J Clin Lab Anal 1992;6:47–53.
   PubMed Web of Science ®Google Scholar
• Capeillère-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta 2004;1689:91–102.
   PubMed Web of Science ®Google Scholar
• Matteucci E, Biasci E, Giampietro O. Advanced oxidation protein products in plasma: stability during storage and correlations with other clinical characteristics. Acta Diabetol 2001;38:187–189.
   PubMed Web of Science ®Google Scholar
• Buonocore G, Perrone S, Longini M, Terzuoli L, Bracci R. Total hydroperoxide and advanced oxidation protein products in preterm hypoxic babies. Pediatr Res 2000;47:221–224.
   PubMed Web of Science ®Google Scholar
• Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002; 162:221–225.
   PubMed Web of Science ®Google Scholar
• Kalousova M, Skrha J, Zima T. Advanced glycation end- products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002;51:597–604.
   PubMed Web of Science ®Google Scholar
• Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003;34: 1563–1574.
   PubMed Web of Science ®Google Scholar
• Piwowar A, Knapik-Kordecka M, Warwas M. Markers of oxidative protein damage in plasma and urine of type 2 diabetic patients. Br J Biomed Sci 2009;66:194–199.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004;116:595–600.
   PubMed Web of Science ®Google Scholar
• Yazici C, Köse K, Calis M, Kuzugüden S, Kirnap M. Protein oxidation status in patients with ankylosing spondylitis. Rheumatology (Oxford) 2004;43:1235–1239.
   PubMed Web of Science ®Google Scholar
• Yazici C, Köse K, Calis M, Demir M, Kirnap M, Ates F. Increased advanced oxidation protein products in Behçet's disease: a new activity marker? Br J Dermatol 2004;151: 105–111.
   PubMed Web of Science ®Google Scholar
• Selmeci L, Seres L, Antal M, Lukács J, Regöly-Mérei A, Acsády G. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple, fast and inexpensive automated technique. Clin Chem Lab Med 2005;43:294–297.
   PubMed Web of Science ®Google Scholar
• Chiu-Braga YY, Hayashi SY, Schafranski M, Messias-Reason IJ. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). Int J Cardiol 2006;109: 275–276.
   Google Scholar
• Fialova L, Malbohan I, Kalousova M, Soukupova J, Krofta L, Stipek S, Zima T. Oxidative stress and inflammation in pregnancy. Scand J Clin Lab Invest 2006;66:121–127.
   PubMed Web of Science ®Google Scholar
• Chang D, Wang F, Zhao YS, Pan HZ. Evaluation of oxidative stress in colorectal cancer patients. Biomed Environ Sci 2008; 21:286–289.
   PubMed Web of Science ®Google Scholar
• Zhou FL, Zhang WG, Wei YC, Meng S, Bai GG, Wang BY, . Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem 2010;285: 15010–15015.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Nguyen-Khoa T, Jungers P, Drüeke TB, Descamps-Latscha B. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol Dial Transplant 1999;14(Suppl 1):76–78.
   Google Scholar
• Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P, . Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta 2007; 379:87–94.
   PubMed Web of Science ®Google Scholar
• Anderstam B, Ann-Christin BH, Valli A, Stenvinkel P, Lindholm B, Suliman ME. Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. Clin Chim Acta 2008;393:114–118.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004;142: 231–255.
   PubMed Web of Science ®Google Scholar
• Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991;91:31S–38S.
   PubMed Web of Science ®Google Scholar
• Dean RT, Fu S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997;324:1–18.
   PubMed Web of Science ®Google Scholar
• Cloos PA, Christgau S. Non-enzymatic covalent modifications of proteins: mechanisms, physiological consequences and clinical applications. Matrix Biol 2002;21:39–52.
   PubMed Web of Science ®Google Scholar
• Davies MJ. The oxidative environment and protein damage. Biochim Biophys Acta 2005;1703:93–109.
   PubMed Web of Science ®Google Scholar
• Pattison DI, Hawkins CL, Davies MJ. What are the plasma targets of the oxidant hypochlorous acid? A kinetic modeling approach. Chem Res Toxicol 2009;22:807–817.
   PubMed Web of Science ®Google Scholar
• Gutteridge JM. Antioxidant properties of the proteins caeruloplasmin, albumin and transferrin. A study of their activity in serum and synovial fluid from patients with rheumatoid arthritis. Biochim Biophys Acta 1986;869:119–127.
   PubMed Web of Science ®Google Scholar
• Halliwell B. Albumin – an important extracellular antioxidant? Biochem Pharmacol 1988;37:569–571.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990;280:1–8.
   PubMed Web of Science ®Google Scholar
• Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett 2008;582:1783–1787.
   PubMed Web of Science ®Google Scholar
• Bourdon E, Blache D. The importance of proteins in defense against oxidation. Antioxid Redox Signal 2001;3:293–311.
   PubMed Web of Science ®Google Scholar
• Bourdon E, Loreau N, Lagrost L, Blache D. Differential effects of cysteine and methionine residues in the antioxidant activity of human seum albumin. Free Radic Res 2005;39: 15–20.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Descamps-Latscha B. Advanced oxidation protein products: novel uremic toxins and pro-inflammatory mediators in chronic renal failure? Nephrol Dial Transplant 1997;12:1310–1312.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000;58:2571–2578.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60:358–363.
   PubMed Web of Science ®Google Scholar
• Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren Fail 2001;23: 563–571.
   PubMed Web of Science ®Google Scholar
• Anraku M, Kitamura K, Shinohara A, Adachi M, Suenga A, Maruyama T, . Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 2004;66:841–848.
   PubMed Web of Science ®Google Scholar
• Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M. The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005;334: 1322–1328.
   PubMed Web of Science ®Google Scholar
• Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, . Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 2004;66:1988–1993.
   PubMed Web of Science ®Google Scholar
• Terawaki H, Nakayama K, Matsuyama Y, Nakayama M, Sato T, Hosoya T, . Dialyzable uremic solutes contribute to enhanced oxidation of serum albumin in regular hemodialysis patients. Blood Purif 2007;25:274–279.
   PubMed Web of Science ®Google Scholar
• Lim PS, Cheng YM, Yang SM. Impairments of the biological properties of serum albumin in patients on hemodialysis. Nephrology (Carlton) 2007;12:18–24.
   PubMed Web of Science ®Google Scholar
• Iwao Y, Anraku M, Hiraike M, Kawai K, Nakajou K, Kai T, . The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metab Pharmacokinet 2006;21: 140–146.
   PubMed Web of Science ®Google Scholar
• Pieniazek A, Brzeszczynska J, Kruszynska I, Gwozdzinski K. Investigation of albumin properties in patients with chronic renal failure. Free Radic Res 2009;43:1008–1018.
   Web of Science ®Google Scholar
• Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, . Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001;60:1844–1850.
   PubMed Web of Science ®Google Scholar
• Morena M, Cristol JP, Bosc JY, Tetta C, Forret G, Leger CL, . Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant 2002;17:422–427.
   PubMed Web of Science ®Google Scholar
• Kalousova M, Zima T, Tesar V, Lachmanova J. Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif 2002;20: 531–536.
   PubMed Web of Science ®Google Scholar
• Kalousova M, Sulkova S, Fialova L, Soukupova J, Malbohan IM, Spacek P, . Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant 2003;18:2577–2581.
   PubMed Web of Science ®Google Scholar
• Descamps-Latscha B, Witko-Sarsat V. Oxidative stress in chronic renal failure and hemodialysis. Nephrologie 2003;24: 377–379.
   Google Scholar
• Fialova L, Kalousova M, Soukupova J, Sulkova S, Merta M, Jelinkova E, . Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities. Kidney Blood Press Res 2004;27:88–95.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chen JS, Wu WM, Liao TN, Chu P, Lin SH, . Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant 2005;20: 1134–1139.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimbürger O, Lindholm B, Stenvinkel P. Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. Atherosclerosis 2005;180:333–340.
   PubMed Web of Science ®Google Scholar
• Coskun C, Kural A, Döventas Y, Koldas M, Ozturk H, Inal BB, Gümüs A. Hemodialysis and protein oxidation products. Ann N Y Acad Sci 2007;1100:404–408.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, . Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524–2532.
   PubMed Web of Science ®Google Scholar
• Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl 2001;78:S108–S113.
   Google Scholar
• Capeillère-Blandin C, Gausson V, Nguyen AT, Descamps-Latscha B, Drüeke T, Witko-Sarsat V. Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Trasplant 2006;21:1555–1563.
   PubMed Web of Science ®Google Scholar
• wao Y, Nakajou K, Nagai R, Kitamura K, Anraku M, Maruyama T, Otagiri M. CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products. Am J Physiol Renal Physiol 2008;295: F1871–F1880.
   Google Scholar
• Marsche G, Frank S, Hrzenjak A, Holzer M, Dirnberger S, Wadsack C, . Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 2009;104:750–757.
   PubMed Web of Science ®Google Scholar
• Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol 1972;22: 681–700.
   PubMedGoogle Scholar
• Herrick S, Blanc-Brude O, Gray A, Laurent G. Fibrinogen. Int J Biochem Cell Biol 1999;31:741–746.
   PubMed Web of Science ®Google Scholar
• Lipinski B, Federman SM, Krolewsky AS. Plasma macromolecular protein complex: interaction with fibrin and fibrinolysis. Thromb Res 1995;78:461–465.
   PubMed Web of Science ®Google Scholar
• Kunitake ST, Carilli CT, Lau K, Protter AA, Naya-Vigne J, Kane JP. Identification of proteins associated with apolipoprotein A-I- containing lipoproteins purified by selected-affinity immunosorption. Biochemistry 1994;33:1988–1993.
   Google Scholar
• Ernst A, Helmhold M, Brunner C, Pethö-Schramm A, Armstrong VW, Müller HJ. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995;270: 6227–6234.
   Google Scholar
• Park CT, Wright SD. Fibrinogen is a component of a novel lipoprotein particle: factor H-related protein (FHRP)-associated lipoprotein particle (FALP). Blood 2000;95: 198–204.
   PubMedGoogle Scholar
• Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 1994;17:429–437.
   PubMed Web of Science ®Google Scholar
• Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000;32:307–326.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Takiuchi H, Matsushima A, Inada Y. Functional consequences of tryptophan modification in human fibrinogen. Biochim Biophys Acta 1978;536:70–77.
   Google Scholar
• Olinescu RM, Kummerow FA. Fibrinogen is an efficient antioxidant. J Nutr Biochem 2001;12:162–169.
   PubMed Web of Science ®Google Scholar
• Abudu N, Miller JJ, Levinson SS. Fibrinogen is a co- antioxidant that supplements the vitamin E analog trolox in a model system. Free Radic Res 2006;40:321–331.
   Web of Science ®Google Scholar
• Kaplan IV, Attaelmannan M, Levinson SS. Fibrinogen is an antioxidant that protects β-lipoproteins at physiological concentrations in a cell free system. Atherosclerosis 2001;158: 455–463.
   PubMed Web of Science ®Google Scholar
• Schwedler S, Schinzel R, Vaith P, Wanner C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation, or causal relationship? Kidney Int Suppl 2001;78:S32–S36.
   Google Scholar
• Giordano M, De Feo P, Lucidi P, dePascale E, Giordano G, Infantone L, . Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. J Am Soc Nephrol 2001;12:349–354.
   PubMed Web of Science ®Google Scholar
• Kirmizis D, Tsiandoulas A, Pangalou M, Koutoupa E, Rozi P, Protopappa M, Barboutis K. Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Med Sci Monit 2006;12:CR55–CR62.
   Google Scholar
• Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, . Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39–47.
   PubMed Web of Science ®Google Scholar
• Lipinski B, Lipinska I, Kato Y. Is the macromolecular protein complex (MPC) a marker for oxidative stress in diabetes mellitus? Diabetologia 2001;44:1356 (Letter to the editor).
   Google Scholar
• Lipinski B. Markers of oxidative stress in uremia. Kidney Int 2004;65:339–340 (Letter to the editor).
   Google Scholar
• Selmeci L, Székely M, Soós P, Seres L, Klinga N, Geiger A, Acsády G. Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res 2006;40:952–958.
   PubMed Web of Science ®Google Scholar
• Lane DA, Ireland H, Knight I, Wolff S, Kyle P, Curtis JR. The significance of fibrinogen derivatives in plasma in human renal failure. Br J Haematol 1984;56:251–260.
   PubMed Web of Science ®Google Scholar
• Kozek-Langenecker SA, Masaki T, Mohammad H, Green W, Mohammad SF, Cheung AK. Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int 1999;56:299–305.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Cojocaru M, Unsworth E, Knecht A, Martin BM. Search for peptidic “middle molecules” in uremic sera: isolation and chemical identification of fibrinogen fragments. J Chromatogr B Analyt Technol Biomed Life Sci 2003;796: 141–153.
   PubMed Web of Science ®Google Scholar
• Thekkedath UR, Chirananthavat T, Leypoldt JK, Cheung AK, Mohammad SF. Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa. Am J Hematol 2006;81:915–926.
   Google Scholar
• Korte W, Riesen WF. Comparability of serum and plasma concentrations of haemostasis activation markers. Clin Chem Lab Med 2001;39:627–630.
   PubMedGoogle Scholar
• Doolittle RF. The evolution of vertebrate fibrinogen. Fed Proc 1976;35:2145–2149.
   PubMedGoogle Scholar
• Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70:247–299.
   PubMedGoogle Scholar
• Doolittle RF. Coagulation in vertebrates with a focus on evolution and inflammation. J Innate Immun 2011;3: 9–16.
   PubMed Web of Science ®Google Scholar
• Kairies N, Beisel HG, Fuentes-Prior P, Tsuda R, Muta T, Iwanaga S, . The 2.0-A crystal structure of tachylectin 5A provides evidence for the common origin of the innate immunity and the blood coagulation system. Proc Natl Acad Sci USA 2001;98:13519–13524.
   Google Scholar
• Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann N Y Acad Sci 2001;936:580–593.
   PubMed Web of Science ®Google Scholar
• Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu QT, Miller CG, . Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987;84:3224–3228.
   PubMedGoogle Scholar
• McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, . cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132–137.
   PubMed Web of Science ®Google Scholar
• Lawn RM, Schwartz K, Patthy L. Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proc Natl Acad Sci USA 1997;94:11992–11997.
   PubMed Web of Science ®Google Scholar
• Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989;86:3847–3851.
   PubMedGoogle Scholar
• Selmeci L, Seres L, Soós P, Székely M, Acsády G. Kinetic assay for the determination of the oxidative stress biomarker, advanced oxidation protein products (AOPP) in the human blood plasma. Acta Physiol Hung 2008;95: 209–218.
   PubMedGoogle Scholar
• Selmeci L, Seres L, Székely M, Soós P, Acsády G. Assay of oxidized fibrinogen reactivity (OFR) as a biomarker of oxidative stress in human plasma: the role of lysine analogs. Clin Chem Lab Med 2010;48:379–382.
   Google Scholar
• Klose R, Fresser F, Kochl S, Parson W, Kapetanopoulos A, Fruchart-Najib J, . Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta- and gamma-chains. J Biol Chem 2000;275:38206–38212.
   PubMedGoogle Scholar
• Tsurupa G, Yakovlev S, Pechik I, Lamanuzzi LB, Anglés-Cano E, Medved L. Interaction of fibrin(ogen) with apolipoprotein(a): further characterization and identification of a novel lysine-dependent apolipoprotein(a)-binding site within the gamma chain 287-411 region. Biochemistry 2006; 45:10624–10632.
   Google Scholar
• Tsurupa G, Ho-Tin-Noé B, Anglés-Cano E, Medved L. Identification and characterization of novel lysine- independent apolipoprotein(a)-binding sites in fibrin(ogen) α-C-domains. J Biol Chem 2003;278:37154–37159.
   Google Scholar
• Yakovlev S, Makogonenko E, Kurochkina N, Nieuwenhuizen W, Ingham K, Medved L. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. Biochemistry 2000;39:15730–15741.
   Google Scholar
• Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003;89: 409–419.
   PubMed Web of Science ®Google Scholar
• Medved L, Tsurupa G, Yakovlev S. Conformational changes upon conversion of fibrinogen into fibrin. The mechanisms of exposure of cryptic sites. Ann N Y Acad Sci 2001;936: 185–204.
   PubMed Web of Science ®Google Scholar
• Tsurupa G, Medved L. Fibrinogen alpha C domains contain cryptic plasminogen and tPA binding sites. Ann N Y Acad Sci 2001;936:328–330.
   PubMed Web of Science ®Google Scholar
• Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082–1085.
   PubMed Web of Science ®Google Scholar
• Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477–1482.
   PubMed Web of Science ®Google Scholar
• Bini A, Kudryk BJ. Fibrinogen in human atherosclerosis. Ann N Y Acad Sci 1995;748:461–471.
   Google Scholar
• Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang JL, Rubin EM, Lawn RM. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997;100:558–564.
   PubMed Web of Science ®Google Scholar
• Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA 1998;95:12591–12595.
   PubMedGoogle Scholar
• Anglès-Cano E, de la Pena Diaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001;936: 261–275.
   PubMed Web of Science ®Google Scholar
• Thornalley PJ, Rabbani N. Protein damage in diabetes and uremia – identifying hotspots of proteome damage where minimal modification is amplified to marked pathophysiological effect. Free Radic Res 2011;45:89–100.
   Web of Science ®Google Scholar
• Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62: 1524–1538.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009;22: 636–643.
   PubMed Web of Science ®Google Scholar